A new clinical trial suggests that pairing bispecific antibodies and antibody-drug conjugates with CAR T-cell therapy may sharply boost one-year progression-free survival for people with aggressive ...
MedPage Today on MSN
Bispecifics Before CAR-T May Be Best-Bet Sequence for Large B-Cell Lymphoma
The use of bispecific antibodies (BsAb) before chimeric antigen receptor T-cell therapy (CAR-T) appeared to be a more optimal ...
Burkitt's lymphoma is a rare and aggressive blood cancer characterized by a translocation of the MYC gene. It occurs most ...
SOUTH SAN FRANCISCO, Calif., Dec. 07, 2025 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a clinical-stage company advancing a pipeline of next-generation chimeric antigen receptor (CAR) ...
Researchers reveal ELI-002 2P cancer vaccine shows promise in boosting immune responses for colorectal and pancreatic cancer ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback